DNA Nanobots has secured a $3.5 million investment from a prominent family office as it advances a non-viral gene delivery platform built around self-assembling nanoscale therapeutics. The Columbus, Ohio-based company said the funding extends its operational runway for the next 18 months and will support continued development of its programmable gene delivery technology.
The company said the $3.5 million financing represents the successful completion of $3.5 million of its $5 million seed round and that it is seeking an additional $1.5 million to reach the full seed target. DNA Nanobots said completion of the seed round would enable it to initiate IND-enabling studies and prepare for first-in-human clinical trials.
DNA Nanobots is developing targeted nanomedicines using DNA self-assembly, often called DNA origami, to engineer structures that carry and release therapeutic payloads directly to diseased cells. The company said its approach aims to increase specificity, reduce systemic toxicity, and improve treatment efficacy. It positions the platform as a way to deliver genes that are difficult to provide with existing methods.
DNA Nanobots said the new capital will primarily be used to advance preclinical work by optimizing and testing its self-assembling designs, expand production capabilities through in-house manufacturing infrastructure improvements for larger batch runs and better reproducibility, broaden the intellectual property portfolio around its core technology, and make strategic hires across molecular biology, nanotechnology, and engineering.
The company also received support from the Ohio Life Sciences Association, which highlighted the financing as an indicator of continued investment into Ohio-based life sciences companies and Ohio State-related innovation.
KEY QUOTES:
“We’re excited to see Ohio Life Sciences member DNA Nanobots secure $3.5 million in funding, a strong signal of confidence in Ohio’s life sciences ecosystem,” said Eddie Pauline, President and CEO of Ohio Life Sciences Association.
Eddie Pauline, President And CEO Of Ohio Life Sciences Association
“We are very pleased to have successfully completed $3.5 million of our $5 million Seed round. This financing provides the capital needed to advance our programs and execute key value-creating milestones in 2026,” said Jim Lynch, CEO of DNA Nanobots. “We are grateful for the strong support from our investors who have re-invested and share our vision and confidence in our strategy and team.”
Jim Lynch, CEO Of DNA Nanobots
“We’re excited to see Ohio Life Sciences member DNA Nanobots secure $3.5 million in funding, a strong signal of confidence in Ohio’s life sciences ecosystem,” said Eddie Pauline, President and CEO of Ohio Life Sciences Association. “It’s encouraging to see capital flowing into Ohio-based companies, including innovative Ohio State spinouts that showcase the strength of our research, commercialization, and homegrown innovation.”
Eddie Pauline, President And CEO Of Ohio Life Sciences Association
